Navigation Links
Assessing the value of treatments to increase height
Date:3/31/2011

CLEVELAND -- Dr. Leona Cuttler, a pediatric endocrinologist and growth hormone expert from University Hospitals Rainbow Babies and Children's Hospital, is the co-author of an editorial in the New England Journal of Medicine commenting on a new study that found giving girls with Turner syndrome low doses of estrogen, as well as growth hormone, years before the onset of puberty, increases their height and offers other benefits.

With her co-author Dr. Robert L. Rosenfield, a pediatric endocrinologist with the University of Chicago Medical Center, Dr. Cuttler writes, "The use of growth hormone and estrogen has a long and often controversial history in the manipulation of growth."

About the new study, they write that the results confirm those of previous, less rigorous studies showing that treatment with growth hormone significantly increased adult height in patients with Turner's syndrome.

Drs. Cuttler and Rosenfield say the results suggest a modest but intriguing synergism between growth hormone and low-dose estrogen in promoting growth.

"The impact of these findings on practice and policy will depend not only on their statistical significance but also on whether the observed changes in height translate into clinically meaningful benefit. The ability to increase height should not be the sole yardstick for assessing benefit," the editorial states.

"Since growth hormone is well entrenched in the management of Turner's syndrome, the current findings support this aspect of practice but are not likely to change it. Yet the results underscore the need for a measured approach, which includes avoiding unrealistic expectations, when families embark on growth hormone therapy. The early use of low-dose estrogen in conjunction with growth hormone is an interesting possibility. An optimal estrogen-replacement regimen could potentially shorten the period of growth hormone treatment, reduce costs, and improve patient satisfaction. However, implementation would be hampered by the lack of a convenient means to deliver the very small estrogen doses that seem to be optimal for height augmentation."

The authors advise caution when considering supplementing growth hormone treatment with early, low-dose estrogen in Turner's syndrome. "The current results show trends that do not consistently reach significance and show only modest synergy between growth hormone and estrogen in achieving height augmentation, as compared with growth hormone alone. The suggested potential benefits of estrogen on cognition are based on earlier short-term data, and long-term data are needed. We must be concerned about unexpected risks posed by estrogen, being mindful of surprising adverse outcomes of estrogen use in other settings," they write.

According to the National Institutes of Health, Turner syndrome occurs in 1 out of 2,500 female births worldwide and develops when a female (X) sex chromosome is missing in cells or is abnormal. These girls are typically of short stature and have a loss of ovarian function.


'/>"/>

Contact: George Stamatis
george.stamatis@UHhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. Mortality rates are an unreliable metric for assessing hospital quality, study finds
2. Assessing positive outcomes of phase III trials
3. Researchers validate a new test for assessing childrens and teenagers fitness to prevent morbidity
4. Assessing the science behind health claims
5. An appeal to the caregiving values of rural women for breast cancer prevention
6. Mayo Clinic researchers confirm value of therapeutic hypothermia after cardiac arrest
7. Study: Consumers value safer food more than current analyses suggest
8. Supporters and opponents of a special blessing for homosexuals share many values
9. Does Club Drug Ecstasy Have Therapeutic Value?
10. Brief clarifies Social Securitys value for women
11. Biological diversity of ovarian cancer lessens value of screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... , ... Steve Helwig & Associates Insurance & Financial, serving the families of ... up with Citizens Opposed to Domestic Abuse in support of its efforts to provide ... victimized by the fear of violence in their own homes, donations may now be ...
(Date:2/8/2016)... San Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... helped raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently ... who also was the American Cancer Society’s 2015 CEO of the Year , ...
(Date:2/8/2016)... IL (PRWEB) , ... February 08, 2016 , ... ... conditions that co-occur frequently. While a significant number of women and men with ... not the trauma itself, that best predicts the development of an eating disorder. ...
(Date:2/8/2016)... Encinitas, CA (PRWEB) , ... February 08, 2016 ... ... study showing greater than 50% lower incidence rate of type 2 diabetes in ... national averages. ”It is time to make a change in public health,” states ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua Rosenthal, PhD, ... healthcare companies can use newly released government data on populations and physicians to ... intervene and capture the value they create to succeed in new economic models ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016 /PRNewswire/--  Cell Applications, Inc. ... tissue-engineering services are now available in ... three-dimensional (3D) bioprinting approach called the "Kenzan Method." ... , a state-of-the-art robotic system that fabricates 3D ... powerful pay-for-service bio-printing model that makes scaffold-free tissue ...
(Date:2/8/2016)... , Feb. 8, 2016  Avista Pharma Solutions ... Eric Setzer as Chief Financial Officer (CFO). Mr. Setzer ... years of experience in various roles within growing technology ... he served as the Executive Director of Finance at ... Raleigh, NC . Previously, Mr. Setzer ...
(Date:2/8/2016)... -- Velano Vascular, a medical technology company transforming and ... practitioners, announced today that the company has raised an ... proceeds from this financing, an extension of a $5 ... support the development and commercialization of the company,s inpatient ... Philadelphia , and a number of ...
Breaking Medicine Technology: